In 2017, major reforms to the regulation of drugs and medical devices were brought in by CFDA (Now NMPA). One key outcome of these changes is that clinical data from an overseas multi-center trial can be used in order to accelerate the approval process of drugs developed by foreign companies. Such reform has been driving active dialogue between China and western companies since.
- 5+ Deals Per Month
- $11+ Million Average Upfront Payment
- $70+ Million Totally Deal Average
- Unique Format
- Private and Focused
- Immediate Follow-Up Meetings
- On-Target Partnering
Meanwhile, we also offer FREE Consultation on partnership with China. Please contact [email protected] to schedule an appointment.
“I attended and presented my company at the private pitch session conducted by MyBioGate at China [email protected] JPM week. In all the decades that I have been involved in partnering and fund-raising, I must say that the private pitch session was the most efficient and productive 5 minute presentation I have ever made. I also saw how this program worked for many other CEOs, in obtaining instant meetings with investors and medical company executives. Amazing! For me, this meeting and the associated networking enabled me to meet and talk with Starlink Capital, JITRI, PHARSCIN PHARMA, Cedrus Group, Accent, ANLONG, LIVZON, LILLY, BAYER, PFIZER, AISLING, KATAI CAPITAL, CELLO HEALTH, SHENZHEN SHIYU INVESTMENT, QILU PHARMA and BUTTON CAPITAL. A great meeting and MyBioGate team effort to be sure! “
-Lonnie Bookbinder, MBA, PhD, CEO ARIZ Precision Medicine